Skip to main content
. Author manuscript; available in PMC: 2013 Jun 7.
Published in final edited form as: Br J Haematol. 2009 Aug 21;147(3):347–351. doi: 10.1111/j.1365-2141.2009.07864.x

Figure 1. Overall Survival (left panel) and event-free survival (right panels) from start of Total Therapy 2 (TT2, both arms combined) and of Total Therapy 3 (TT3) relative to delTP53.

Figure 1

Figure 1

Figure 1

a: In gene expression profiling-defined low-risk myeloma: In the case of TT2, del-TP53 imparts inferior overall survival and event-free survival, regardless of randomization to control or thalidomide arm (data not shown). By contrast, neither overall nor event-free survival was adversely affected In the case of TT3.

b: In gene expression profiling-defined high-risk myeloma: Del-TP53 imparts inferior overall and event-free survival in TT3, whereas outcomes were equally poor in both TT2 arms.

c: In the context of gene expression profiling-defined FGFR3-type myeloma (present, FGFR3+; absent, FGFR3−): Among patients treated with TT2, delTP53 was associated with shorter overall and event-free survival regardless of FGFR3 status (FGFR3−: compare c and g curves [p=0.0001; p=0.001]; FGFR3+: compare d and h curves [p=0.05; p=0.08]). In case of TT3, overall survival was inferior and a trend was noted for event-free survival in the absence of FGFR3 (FGFR3−: compare a and e curves [p=0.02; p=0.08]); no difference was observed in the presence of FGFR3 (FGFR3+: compare b and f curves [p=0.24; p=0.16]). Viewed differently, FGFR3+ adversely affected both clinical endpoints in TT2 in the absence of delTP53 (compare curves c and d [p=0.0004; p=0.001]) with trends present in delTP53’s presence (compare g and h curves [p=0.25; p=0.10]). In the case of TT3, FGFR3+ failed to affect outcomes both in the absence of delTP53 (compare a and b curves [p=0.22; p=0.72]) and in the presence of delTP53 (compare curves e and f [p=0.65; p=0.79]).